NASDAQ:AIXC Qualigen Therapeutics (AIXC) Stock Price, News & Analysis $1.01 +0.02 (+1.90%) As of 12:26 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock About Qualigen Therapeutics Stock (NASDAQ:AIXC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Qualigen Therapeutics alerts:Sign Up Key Stats Today's Range$0.94▼$1.1150-Day Range$0.92▼$1.5052-Week Range$0.90▼$8.81Volume17,915 shsAverage Volume74,238 shsMarket Capitalization$20.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. Read More Qualigen Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreAIXC MarketRank™: Qualigen Therapeutics scored higher than 3% of companies evaluated by MarketBeat, and ranked 96th out of 97 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingQualigen Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageQualigen Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Qualigen Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Qualigen Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Qualigen Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.81% of the float of Qualigen Therapeutics has been sold short.Short Interest Ratio / Days to CoverQualigen Therapeutics has a short interest ratio ("days to cover") of 0.62, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Qualigen Therapeutics has recently increased by 104.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQualigen Therapeutics does not currently pay a dividend.Dividend GrowthQualigen Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.06 News SentimentQualigen Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Qualigen Therapeutics this week, compared to 3 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Qualigen Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.17% of the stock of Qualigen Therapeutics is held by insiders.Percentage Held by Institutions3.18% of the stock of Qualigen Therapeutics is held by institutions.Read more about Qualigen Therapeutics' insider trading history. Receive AIXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AIXC Stock News HeadlinesTrevena (NASDAQ:TRVN) & Qualigen Therapeutics (NASDAQ:AIXC) Critical ComparisonJuly 10, 2026 | americanbankingnews.comAIxCrypto Debuts at Automate 2026, Unveiling Its EAI + Web3 Robot Ecosystem Strategy with the Launch of RoboShare and AIXC01June 22, 2026 | prnewswire.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.July 15 at 1:00 AM | Altimetry (Ad)AIXC AIxCrypto Holdings, Inc.June 19, 2026 | seekingalpha.comAIxCrypto Announces First Quarter 2026 Earnings Release Date and Conference Call DetailsMay 8, 2026 | prnewswire.comAIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Agentir Progress, Chutes AI Collaboration Framework, and Bitcoin 2026 EngagementMay 5, 2026 | prnewswire.comAIxCrypto Announces Strategic Collaboration Framework with Chutes AI to Support AI Agent Infrastructure ScalingApril 30, 2026 | prnewswire.comAIxCrypto's Designated Investor and Faraday Future Complete Amendment to $12 Million Investment Agreement,Exploring RWA-Related Applications and Integration of Real-World Assets with Blockchain InfrastructureApril 17, 2026 | prnewswire.comSee More Headlines AIXC Stock Analysis - Frequently Asked Questions How have AIXC shares performed this year? Qualigen Therapeutics' stock was trading at $2.17 on January 27, 2026. Since then, AIXC stock has decreased by 50.7% and is now trading at $1.07. How were Qualigen Therapeutics' earnings last quarter? Qualigen Therapeutics, Inc. (NASDAQ:AIXC) posted its earnings results on Tuesday, May, 12th. The company reported ($0.79) earnings per share for the quarter. How do I buy shares of Qualigen Therapeutics? Shares of AIXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2026Today7/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 AIXC's financial health is in the Red zone, according to TradeSmith. AIXC has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AIXC CIK1460702 WebN/A Phone(760) 918-9165Fax760-918-9127Employees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)($6.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-771.52% Return on Assets-79.52% Debt Debt-to-Equity RatioN/A Current Ratio11.57 Quick Ratio11.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.75) per share Price / Book-1.35Miscellaneous Outstanding Shares20,240,000Free Float19,998,000Market Cap$20.42 million OptionableN/A Beta0.49 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:AIXC) was last updated on 7/15/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
